ellaOne

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

ulipristal

Available from:

Laboratoire HRA Pharma

ATC code:

G03AD02

INN (International Name):

ulipristal acetate

Therapeutic group:

- Ormoni tas-sess u modulaturi ta ' l-ġenitali-sistema , kontraċettivi Emerġenza

Therapeutic area:

Kontraċezzjoni, Postcoital

Therapeutic indications:

Kontraċezzjoni ta 'emerġenza fi żmien 120 siegħa (ħamest ijiem) ta' kopulazzjoni sesswali mhux protetta jew falliment ta 'kontraċezzjoni.

Product summary:

Revision: 30

Authorization status:

Awtorizzat

Authorization date:

2009-05-15

Patient Information leaflet

                                37
B. FULJETT TA’ TAGĦRIF
38
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
ELLAONE 30 MG PILLOLA
Ulipristal acetate
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA,
MEDIĊINA PERESS LI FIH
INFORMAZZJONI IMPORTANTI GĦALIK.
Dejjem ħu din il-mediċina eżatt kif deskritt f’dan il-fuljett jew
kif qallek it-tabib, l-ispiżjar jew il-
professjonist ieħor fil-kura tas-saħħa tiegħek.
•
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
•
Staqsi lill-ispiżjar tiegħek jekk tkun trid aktar informazzjoni jew
pariri..
•
Jekk ikollok xi effett sekondarju, kellem -ispiżjar, lit-tabib jew
lill-professjonist ieħor fil-kura
tas-saħħa tiegħek. Dan jinkludi xi effett sekondarju possibbli li
mhuwiex elenkat f’dan il-fuljett.
Ara sezzjoni 4.
F’DAN IL-FULJETT
:
1.
X’inhu ellaOne u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu ellaOne
3.
Kif għandek tieħu ellaOne
4.
Effetti sekondarji possibbli
5.
Kif taħżen ellaOne
6.
Kontenut tal-pakkett u informazzjoni oħra
-
Informazzjoni utli dwar il-kontraċezzjoni
1.
X’INHU ELLAONE U GЋALXIEX JINTUŻA
ellaOne huwa kontraċettiv emerġenza
ellaOne huwa kontraċettiv maħsub biex jevita t-tqala wara sess mhux
protett jew jekk il-metodu
kontraċettiv tiegħek ma jkunx ħadem. Pereżempju:
-
jekk għamilt sess mingħajr protezzjoni;
-
jekk il-kondom tiegħek jew tas-sieħeb tiegħek tqatta’, żelaq jew
ħareġ, jew jekk insejt tuża
wieħed;
-
jekk ma ħadtx il-pillola kontraċettiva tiegħek kif irrakkomandat.
Għandek tieħu l-pillola mill-aktar fis possibbli wara s-sess, u sa
mhux aktar tard minn 5 ijiem wara
(120 siegħa).
Dan għaliex huwa iktar effettiv jekk teħodha kemm jista’ jkun
malajr wara sess mhux protett.
Din il-mediċina hija xierqa għal kwalunkwe mara li tkun fl-età li
tista’ toħroġ tqila, inkluż l-
adolexxenti.
Tista’ tieħu l-pillola fi kwalunkwe mument matul iċ-ċiklu
mestrwali.
ellaOne ma jaħdimx jekk inti diġà tqila.
Jekk il-mestrwazzjoni tiegħek tkun tard, teżisti l-possibb
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
ellaOne 30 mg pillola
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Kull pillola fiha 30 mg ulipristal acetate.
Eċċipjenti b’effett magħruf
Kull pillola fiha 237 mg ta’ lattożju (bħala monoidrat).
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola
Pillola tonda, ġejja fit-tond, bajda għal kulur il-krema rħamata
ta’ dijametru ta’ 9 mm, imnaqqxa
b’“
_еllа_
” fuq iż-żewġ naħat.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Kontraċezzjoni ta’ emerġenza sa 120 siegħa (5 ijiem) minn att
sesswali mhux protett jew ta’
kontraċettiv li ma ħadimx.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
It-trattament jikkonsisti f’pillola waħda li għandha tittieħed
oralment malajr kemm jista’ jkun, iżda
mhux aktar tard minn 120 siegħa (5 ijiem) wara att sesswali mhux
protett jew ta’ kontraċettiv li ma
ħadimx.
Il-pillola tista’ tittieħed fi kwalunkwe mument matul iċ-ċiklu
mestrwali.
F’każ ta’ rimettar sa 3 sigħat mit-teħid tal-pillola, għandha
tittieħed pillola oħra.
Jekk mestrwazzjoni ta’ mara tkun tard jew f’każ ta’ sintomi
ta’ tqala, għandha tiġi eskluża tqala qabel
ma tingħata l-pillola.
_Popolazzjonijiet speċjali _
_Indeboliment renali _
Mhuwa meħtieġ ebda aġġustament fid-doża.
_Indeboliment epatiku _
Fin-nuqqas ta’ studji speċifiċi, ma jistgħux isiru
rakkomandazzjonijiet alternattivi dwar doża għal
ulipristal acetate
_._
_ _
_Indeboliment epatiku gravi _
Fin-nuqqas ta’ studji speċifiċi, ulipristal acetate mhuwiex
rakkomandat.
_ _
3
_Popolazzjoni pedjatrika _
Ulipristal acetate fi tfal ta’ età qabel il-pubertà m’għandux
użu rilevanti fl-indikazzjoni tal-
kontraċezzjoni ta’ emerġenza
_. _
Adolexxenti:
Ulipristal acetate għal kontraċezzjoni ta’ emerġenza huwa adattat
għal kull mara li tkun fl-età li tista’
toħroġ tqila, inkluż adolexxenti. Ma ntweriet ebda differenza
fis
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-01-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-01-2024
Public Assessment Report Public Assessment Report Bulgarian 06-02-2015
Patient Information leaflet Patient Information leaflet Spanish 26-01-2024
Public Assessment Report Public Assessment Report Spanish 06-02-2015
Patient Information leaflet Patient Information leaflet Czech 26-01-2024
Public Assessment Report Public Assessment Report Czech 06-02-2015
Patient Information leaflet Patient Information leaflet Danish 26-01-2024
Public Assessment Report Public Assessment Report Danish 06-02-2015
Patient Information leaflet Patient Information leaflet German 26-01-2024
Public Assessment Report Public Assessment Report German 06-02-2015
Patient Information leaflet Patient Information leaflet Estonian 26-01-2024
Public Assessment Report Public Assessment Report Estonian 06-02-2015
Patient Information leaflet Patient Information leaflet Greek 26-01-2024
Public Assessment Report Public Assessment Report Greek 06-02-2015
Patient Information leaflet Patient Information leaflet English 26-01-2024
Public Assessment Report Public Assessment Report English 06-02-2015
Patient Information leaflet Patient Information leaflet French 26-01-2024
Public Assessment Report Public Assessment Report French 06-02-2015
Patient Information leaflet Patient Information leaflet Italian 26-01-2024
Public Assessment Report Public Assessment Report Italian 06-02-2015
Patient Information leaflet Patient Information leaflet Latvian 26-01-2024
Public Assessment Report Public Assessment Report Latvian 06-02-2015
Patient Information leaflet Patient Information leaflet Lithuanian 26-01-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-01-2024
Public Assessment Report Public Assessment Report Lithuanian 06-02-2015
Patient Information leaflet Patient Information leaflet Hungarian 26-01-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 26-01-2024
Public Assessment Report Public Assessment Report Hungarian 06-02-2015
Patient Information leaflet Patient Information leaflet Dutch 26-01-2024
Public Assessment Report Public Assessment Report Dutch 06-02-2015
Patient Information leaflet Patient Information leaflet Polish 26-01-2024
Public Assessment Report Public Assessment Report Polish 06-02-2015
Patient Information leaflet Patient Information leaflet Portuguese 26-01-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 26-01-2024
Public Assessment Report Public Assessment Report Portuguese 06-02-2015
Patient Information leaflet Patient Information leaflet Romanian 26-01-2024
Public Assessment Report Public Assessment Report Romanian 06-02-2015
Patient Information leaflet Patient Information leaflet Slovak 26-01-2024
Public Assessment Report Public Assessment Report Slovak 06-02-2015
Patient Information leaflet Patient Information leaflet Slovenian 26-01-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 26-01-2024
Public Assessment Report Public Assessment Report Slovenian 06-02-2015
Patient Information leaflet Patient Information leaflet Finnish 26-01-2024
Public Assessment Report Public Assessment Report Finnish 06-02-2015
Patient Information leaflet Patient Information leaflet Swedish 26-01-2024
Public Assessment Report Public Assessment Report Swedish 06-02-2015
Patient Information leaflet Patient Information leaflet Norwegian 26-01-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 26-01-2024
Patient Information leaflet Patient Information leaflet Icelandic 26-01-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 26-01-2024
Patient Information leaflet Patient Information leaflet Croatian 26-01-2024
Public Assessment Report Public Assessment Report Croatian 06-02-2015

Search alerts related to this product

View documents history